Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Some patients with Parkinson disease (PD) develop pathological gambling when treated with dopamine agonists (DAs). However, little is known about DA-induced changes in neuronal networks that may underpin this drug-induced change in behavior in vulnerable individuals. In this case-control study, we aimed to investigate DA-induced changes in brain activity that may differentiate patients with PD with DA-induced pathological gambling (gamblers) from patients with PD without such a history (controls).
Methods: Following overnight withdrawal of antiparkinsonian medication, patients were studied with H215O PET before and after administration of DA (3 mg apomorphine) to measure changes in regional cerebral blood flow as an index of regional brain activity during a card selection game with probabilistic feedback.
Results: We observed that the direction of DA-related activity change in brain areas that are implicated in impulse control and response inhibition (lateral orbitofrontal cortex, rostral cingulate zone, amygdala, external pallidum) distinguished gamblers from controls. DA significantly increased activity in these areas in controls, while gamblers showed a significant DA-induced reduction of activity.
Conclusions: We propose that in vulnerable patients with PD, DAs produce an abnormal neuronal pattern that resembles those found in nonparkinsonian pathological gambling and drug addiction. DA-induced disruption of inhibitory key functions—outcome monitoring (rostral cingulate zone), acquisition and retention of negative action-outcome associations (amygdala and lateral orbitofrontal cortex)—together with restricted access of those areas to executive control (external pallidum)—may well explain loss of impulse control and response inhibition in vulnerable patients with PD, thereby fostering the development of pathological gambling.
Footnotes
-
Study funding: Supported by the Ontario Problem Gambling Research Centre and Canadian Institutes of Health Research (CIHR) (MOP-64423 to A.P.S.). A.P.S. is supported by the CIHR New Investigator Research Award.
-
- ANOVA
- analysis of variance
- DA
- dopamine agonist
- G-SAS
- Gambling Symptom Assessment Scale
- GPe
- external pallidum
- MNI
- Montréal Neurological Institute
- OFC
- orbitofrontal cortex
- PD
- Parkinson disease
- rCBF
- regional cerebral blood flow
- RCZ
- rostral cingulated zone
- UPDRS
- Unified Parkinson's Disease Rating Scale
Editorial, page 1668.
Supplemental data at www.neurology.org
- Received April 2, 2010.
- Accepted July 19, 2010.
- Copyright © 2010 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Editorials
Pathological gambling in PDDid the devil make me do it?Richard B. Dewey, Jr. et al.Neurology, October 06, 2010 -
Article
Longitudinal analysis of impulse control disorders in Parkinson diseaseJean-Christophe Corvol, Fanny Artaud, Florence Cormier-Dequaire et al.Neurology, June 20, 2018 -
Article
Co-occurrence of apathy and impulse control disorders in Parkinson diseaseBonnie M. Scott, Robert S. Eisinger, Matthew R. Burns et al.Neurology, October 01, 2020 -
Article
Naltrexone for impulse control disorders in Parkinson diseaseA placebo-controlled studyKimberly Papay, Sharon X. Xie, Matthew Stern et al.Neurology, July 18, 2014